Expert Interview
A look at Verona Pharma's ensifentrine for the treatment of chronic obstructive pulmonary disease before the PDUFA on June 26th
Ticker(s): VRNAInstitution: Central Florida Pulmonary Group
- Associate Professor at the University of Central Florida School of Medicine and Director of the Clinical Resource Center for the Alpha-1 Foundation at CFPG
- Treats 3000 patients with COPD
- Special interest in Pulmonary Hypertension, Sleep Disorders, Adult Cystic Fibrosis, Alpha 1 Antitrypsin Deficiency, and Lymphangiolyomyomatosis.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
